Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/36767

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

THIRD-LINE ANTIRETROVIRAL THERAPY IN LOW-INCOME AND MIDDLE-INCOME COUNTRIES (ACTG A5288): A PROSPECTIVE STRATEGY STUDY
Grinsztejn, Beatriz et al. | Date Issued: 2019
Author
Grinsztejn, Beatriz
Hughes, Michael D.
Ritz, Justin
Salata, Robert
Mugyenyi, Peter
Hogg, Evelyn
Wieclaw, Linda
Gross, Robert
Godfrey, Catherine
Cardoso, Sandra W.
Bukuru, Aggrey
Makanga, Mumbi
Faesen, Sharlaa
Mave, Vidya
Wangari Ndege, Beatrice
Nerette Fontain, Sandy
Samaneka, Wadzanai
Secours, Rode
van Schalkwyk, Marije
Mngqibisa, Rosie
Mohapi, Lerato
Valencia, Javier
Sugandhavesa, Patcharaphan
Montalban, Esmelda
Avihingsanon, Anchalee
Santos, Breno R.
Kumarasamy, Nagalingeswaran
Kanyama, Cecilia
Schooley, Robert T.
Mellors, John W.
Wallis, Carole L.
Collier, Ann C.
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Harvard T H Chan School of Public Health, Boston, MA, USA.
Harvard T H Chan School of Public Health, Boston, MA, USA.
Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
Joint Clinical Research Center, Kampala, Uganda.
Social & Scientific Systems, Inc, Silver Spring, MD, USA.
Frontier Science & Technology Research Foundation, Amherst, NY, USA.
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.
Division of AIDS, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Joint Clinical Research Center, Kampala, Uganda.
Kenya Medical Research Institute, Kisumu, Kenya; Center of Disease Control, Kisumu, Kenya.
Wits HIV Clinical Research Site, Johannesburg, South Africa.
BJ Medical College Clinical Research Site, Pune, India.
AMPATH, Moi University Teaching Hospital Eldoret Clinical Research Site, Eldoret, Kenya.
Les Centres GHESKIO Clinical Research Site, Port-au-Prince, Haiti.
University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
Les Centres GHESKIO Clinical Research Site, Port-au-Prince, Haiti.
Family Clinical Research Unit Clinical Research Site, Stellenbosch University, Cape Town, South Africa.
Durban Adult HIV Clinical Research Site, Enhancing Care Foundation, Durban, South Africa.
Soweto AIDS Clinical Trials Group Clinical Research Site, University of the Witwatersrand, Johannesburg, South Africa.
Barranco Clinical Research Site, Lima, Peru.
Center for AIDS and STDs, Chiang Mai University, Chiang Mai, Thailand.
San Miguel Clinical Research Site, Lima, Peru.
Thai Red Cross AIDS Research Center Treatment Clinical Research Site, Bangkok, Thailand.
Serviço de Infectologia, Hospital Nossa Senhora da Conceicao, Grupo Hospitalar Conceição, Porto Alegre, Brazil.
Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India.
University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi.
Division of Infectious Disease, University of California, San Diego, CA, USA.
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Bio Analytical Research Corporation South Africa, Lancet Laboratories, Johannesburg, South Africa.
University of Washington School of Medicine, University of Washington, Seattle, WA, USA.
Abstract
Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring. We aimed to evaluate use of newer antiretroviral drugs and contemporary management approaches, including population-based sequencing, to select appropriate antiretrovirals, plasma viral load monitoring, and interventions to improve adherence in individuals presenting with second-line viral failure.
Keywords
Antiretroviral therapy
HIV-1
Drug resistence
AIDS
 
Publisher
Elsevier
Citation
GRINSZTEJN, Beatriz et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV, v. 6, n. 9, p. e588-e600, Sept. 2019.
DOI
10.1016/S2352-3018(19)30146-8
ISSN
2405-4704
Notes
A5288 Team: Grinsztejn B, Mugyenyi PN, Collier A, Salata R, Godfrey C, Hogg E, Hughes M, Ritz J, Wieclaw L, Sise T, Mellors JW, Wallis C, Fletcher CV, Gandhi M, Gross R, Schooley RT, Walensky R, van Schalkwyk M, Faesen S, Mngqibisa R, Valencia J, Montalban E, Kumarasamy N, Kanyama C, Cardoso SW, Santos BR, Mansfield B, Mugerwa H, Ndege BW, Secours R, Samaneka W, Kadam D, Mave V, Makanga M, Fontain SN, Sugandhavesa P, Avihingsanon A, Nakibuuka L, Nassolo H, Anthony P, Kulkarni V, Nsubuga M, van Wyk J, Rooney J, van Delft Y, Leavitt R, Luk R, Benns A, Hovind L, Shahkolahi A.